EGFR Resisters Co-Founder Ivy Elkins gave a presentation on “Keeping Your Work Focused on Patients” at the IASLC 2022 Targeted Therapies of Lung Cancer Meeting. This presentation was part of a special Early Career Workshop aimed at young investigators and focused on critical topics of interest to them in their developing careers. Ivy spoke about the importance of including patient advocates in research throughout the life cycle of a project and suggested many ways patient advocates could help make both clinical and laboratory research more relevant and meaningful. She also included information about how to find the right advocate for projects.Download the entire presentation slide deck here.
We are a group of lung cancer patients with EGFR mutations who have developed resistance to at least one targeted treatment drug, or who face probable resistance in the future. Caregivers are also welcome. We are here to share treatment experiences, information about clinical trials, breaking news about research developments, and other information with each other.